Cognitive effects of the GSK-3 inhibitor "lithium" in LPS/chronic mild stress rat model of depression: Hippocampal and cortical neuroinflammation and tauopathy

Neurotoxicology. 2021 Mar:83:77-88. doi: 10.1016/j.neuro.2020.12.016. Epub 2021 Jan 6.

Abstract

Low-dose repeated lipopolysaccharide pre-challenge followed by chronic mild stress (LPS/CMS) protocol has been introduced as a rodent model of depression combining the roles of immune activation and chronic psychological stress. However, the impact of this paradigm on cognitive functioning has not been investigated hitherto.

Methods: This study evaluated LPS/CMS-induced cognitive effects and the role of glycogen synthase kinase-3β (GSK-3β) activation with subsequent neuroinflammation and pathological tau deposition in the pathogenesis of these effects using lithium (Li) as a tool for GSK-3 inhibition.

Results: LPS pre-challenge reduced CMS-induced neuroinflammation, depressive-like behavior and cognitive inflexibility. It also improved spatial learning but increased GSK-3β expression and exaggerated hyperphosphorylated tau accumulation in hippocampus and prefrontal cortex. Li ameliorated CMS and LPS/CMS-induced depressive and cognitive deficits, reduced GSK-3β over-expression and tau hyperphosphorylation, impeded neuroinflammation and enhanced neuronal survival.

Conclusion: This study draws attention to LPS/CMS-triggered cognitive changes and highlights how prior low-dose immune challenge could develop an adaptive capacity to buffer inflammatory damage and maintain the cognitive abilities necessary to withstand threats. This work also underscores the favorable effect of Li (as a GSK-3β inhibitor) in impeding exaggerated tauopathy and neuroinflammation, rescuing neuronal survival and preserving cognitive functions. Yet, further in-depth studies utilizing different low-dose LPS challenge schedules are needed to elucidate the complex interactions between immune activation and chronic stress exposure.

Keywords: Chronic mild stress; Cognition; Lipopolysaccharide; Lithium; Neuroinflammation; Tauopathy.

MeSH terms

  • Animals
  • Behavior, Animal / drug effects*
  • Cerebral Cortex / drug effects*
  • Cerebral Cortex / enzymology
  • Cerebral Cortex / physiopathology
  • Chronic Disease
  • Cognition / drug effects*
  • Cognitive Dysfunction / enzymology
  • Cognitive Dysfunction / etiology
  • Cognitive Dysfunction / physiopathology
  • Cognitive Dysfunction / prevention & control*
  • Depression / enzymology
  • Depression / etiology
  • Depression / physiopathology
  • Depression / prevention & control*
  • Disease Models, Animal
  • Encephalitis / enzymology
  • Encephalitis / etiology
  • Encephalitis / physiopathology
  • Encephalitis / prevention & control*
  • Glycogen Synthase Kinase 3 beta / antagonists & inhibitors*
  • Glycogen Synthase Kinase 3 beta / metabolism
  • Hippocampus / drug effects*
  • Hippocampus / enzymology
  • Hippocampus / physiopathology
  • Inflammation Mediators / metabolism
  • Lipopolysaccharides
  • Lithium Chloride / pharmacology*
  • Male
  • Phosphorylation
  • Protein Kinase Inhibitors / pharmacology*
  • Rats
  • Rats, Wistar
  • Spatial Learning / drug effects
  • Stress, Psychological / complications
  • Stress, Psychological / psychology
  • Tauopathies / enzymology
  • Tauopathies / etiology
  • Tauopathies / physiopathology
  • Tauopathies / prevention & control*
  • tau Proteins / metabolism

Substances

  • Inflammation Mediators
  • Lipopolysaccharides
  • Mapt protein, rat
  • Protein Kinase Inhibitors
  • lipopolysaccharide, E coli O55-B5
  • tau Proteins
  • Glycogen Synthase Kinase 3 beta
  • Gsk3b protein, rat
  • Lithium Chloride